Stay informed with our
free newsletters

Gilead and Kite Oncology Demonstrate Broad Leadership in Cell Therapy and Expanding Blood Cancer Pipeline

  • Kites Landmark CAR T-Cell Therapy Study ZUMA-7 in Relapsed/Refractory Large B-Cell Lymphoma to be Featured in ASH Plenary Session.
  • Five Oral Presentations Highlight Kites Leadership in CAR T-Cell Therapies.
  • New Research on Magrolimab Provides Key Insights as Gilead Rapidly Expands Research in AML

Gilead Sciences, Inc.and Kite, a Gilead Company, today announced that data at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition (December 11-14) will showcase continued leadership across both approved and investigational CAR T-cell therapies and medicines. Gilead and Kite will present more than 20 abstracts, including a plenary presentation and six oral presentations, across several hematological malignancies including large B-cell lymphoma (LBCL), non-Hodgkin lymphoma (NHL), acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

“This ASH meeting illustrates the growing maturity of data regarding the potential of our CAR T-cell therapies to be used earlier in treatment along with long-term follow-up data,” said Frank Neumann, MD, PhD, Kite’s Global Head of Clinical Development. “As we continue to build on the established strengths of Kite’s CAR T franchise, our goal is to provide differentiated treatment options to patients that have the potential to change standard of care and deliver the hope of survival to more people with blood cancers.”

In cell therapy, Kite will present the first efficacy and safety results from the landmark ZUMA-7 study in LBCL as part of ASH’s plenary sessions. Additional research from Kite, focused on long-term follow-up data and quality of life improvements for people with certain blood cancers treated with the company’s CAR T-cell therapies, will also be presented.

Next-Generation Biomanufacturing Market - Analysis and Forecast, 2020-2031

Next-Generation Biomanufacturing Market - Analysis and Forecast, 2020-2031

A Global Analysis: Focus on Single-Use and Digital Platform and Segment Analysis for Workflow, Products, Medical Application, End User, Country Data (16 Countries), and Competitive Landscape

Download free sample pages

“The Gilead and Kite data presentations at ASH reinforce our diverse oncology pipeline focused on helping bring more life to people with cancer, especially in areas where few options exist,” said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences. “We see broad potential across our oncology portfolio as we advance transformative science for people with hard-to-treat blood cancers.”

Researchers will also share early-stage research on magrolimab, an investigational CD47 inhibitor, both in an oral session and in an ASH-EHA Joint Symposium. During the symposium, Targeting Macrophages and the Innate Immune System to Treat Hematologic Malignancies, potential new approaches to cancer therapies will be showcased. Early data suggest these approaches, including activating the innate immune system, could become foundational to the next generation of oncology treatment.

Source: Gilead Sciences
Date: Nov 4, 2021
View original News release

Share this news: